Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 940.50K | 453.40K | 38.50K | 41.50K | 20.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 940.50K | 453.40K | 38.50K | 41.50K | 20.10K |
| Cost of Revenue | 530.80K | 190.00K | 8.80K | 17.10K | 2.60K |
| Gross Profit | 409.70K | 263.50K | 29.70K | 24.50K | 17.50K |
| SG&A Expenses | 723.50K | 715.10K | 583.60K | 625.40K | 534.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.39M | 1.26M | 919.70K | 939.30K | 744.30K |
| Operating Income | -448.20K | -806.00K | -881.20K | -897.80K | -724.20K |
| Income Before Tax | -497.60K | -888.70K | -1.11M | -1.09M | -927.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -497.60K | -888.70K | -1.11M | -1.09M | -927.50K |
| Earnings from Discontinued Operations | 53.40K | 7.60M | 72.70K | -39.50K | -100.10K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -444.20K | 6.71M | -1.04M | -1.13M | -1.03M |
| EBIT | -448.20K | -806.00K | -881.20K | -897.80K | -724.20K |
| EBITDA | -414.20K | -766.30K | -863.80K | -946.80K | -679.50K |
| EPS Basic | 0.00 | 0.05 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.04 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 133.79M | 132.36M | 131.84M | 127.12M | 126.80M |
| Average Diluted Shares Outstanding | 133.79M | 158.02M | 131.84M | 127.12M | 126.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
